Johnson & Johnson (JNJ)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$267.34+3.09%
Close 2026-07-07 · 1-day change
Reading JNJ? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track JNJ free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading JNJ? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track JNJ free→QuarterlyIQ Insights · JNJ
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of operations and financial condition On April 14, 2026, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 29, 2026.
Other Events On April 14, 2026, Johnson & Johnson issued the attached press release (Exhibit 99.3) announcing that its Board of Directors declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the cl…
Results of operations and financial condition On January 21, 2026, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the fourth quarter and full year ended December 28, 2025.
Results of operations and financial condition On October 14, 2025, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 28, 2025.
Director — John Morikis: John Morikis was elected to the Board of Directors and will serve on the Audit Committee and Compensation & Benefits Committee.
Results of operations and financial condition On July 16, 2025, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the second quarter ended June 29, 2025.
Director — Daniel Pinto: Daniel Pinto was elected to the Board of Directors effective July 1, 2025.
Director — D. Adamczyk: D. Adamczyk is retiring from the Board of Directors to join Goldman Sachs as a Partner.
Results of operations and financial condition On April 15, 2025, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 30, 2025.
Other Events On April 15, 2025, Johnson & Johnson issued the attached press release (Exhibit 99.3) announcing that its Board of Directors declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend is payable on June 10, 2025 to shareholders of record at the c…
Results of operations and financial condition On January 22, 2025, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the fourth quarter and full year ended December 29, 2024.
Results of operations and financial condition On October 15, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 29, 2024.
Regulation FD Disclosure On September 20, 2024, the Company announced that its subsidiary, Red River Talc LLC (“Red River”), filed a voluntary prepackaged Chapter 11 bankruptcy case today in the in U.S. Bankruptcy Court for the Southern District of Texas Houston Division to fully and finally resolve of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against the Company and its affiliates in the United States. Red River filed the bankruptcy case af…
Director — D. S. Davis: D. S. Davis retired as a Director after the successful transition of responsibilities.
Executive Vice President, Chief Human Resources Officer (CHRO) — Peter M. Fasolo: Peter M. Fasolo has elected to retire from his role as CHRO.
Results of operations and financial condition On July 17, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the second quarter ended June 30, 2024.
Regulation FD Disclosure On May 1, 2024, the Company announced a proposed Plan of Reorganization (the “Proposed Plan”) for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475 billion payable over 25 years (nominal value of approx…
Results of Operations and Financial Condition On May 1, 2024, Johnson & Johnson issued the attached earnings schedules for the first quarter ended March 31, 2024. These schedules have been amended to reflect the information referenced in
Other Events On April 16, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.3) announcing that its Board of Directors declared a 4.2% increase in the quarterly dividend rate, from $1.19 to $1.24 per share, marking the 62nd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $4.96 per share compared to the previous rate of $4.76 per share. The next quarterly dividend is payable on June 4, 2024 to shareholders of record as of the clos…
Results of Operations and Financial Condition On April 16, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 31, 2024.
Results of Operations and Financial Condition On January 23, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the fourth quarter and full year ended December 31, 2023.
Other Events Today, the Company announced its acquisition of Laminar, Inc. As a result of the acquisition, Johnson & Johnson will be adjusting its expected Adjusted Fiscal Year 2023 EPS. The asset acquisition will require an in-process research and development charge which will reduce operational and reported Adjusted EPS by approximately $0.17 from guidance previously issued. The new expected operational and reported Adjusted EPS ranges are now $9.85 to $9.91 and $9.90 to $9.96, respectively…
The filing describes a new deferred compensation plan and modifications to an existing one, which are not management changes.
Executive Vice President, Worldwide Chair MedTech and member of the Executive Committee — Ashley McEvoy: Ashley McEvoy resigned from her position and will depart the Company in the first quarter of 2024.
Results of Operations and Financial Condition On October 17, 2023, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended October 1, 2023.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.